Cardiff Oncology (CRDF) 10-Q 7 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Apr. 30, 2020
Document and Entity Information
Entity Registrant Name	Trovagene, Inc.
Entity Central Index Key	0001213037
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		12,303,274
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 9,277,025	$ 10,195,292
Accounts receivable and unbilled receivable	106,432	203,480
Prepaid expenses and other current assets	899,451	954,957
Total current assets	10,282,908	11,353,729
Property and equipment, net	758,503	877,823
Operating lease right-of-use assets	617,622	697,418
Other assets	156,370	157,576
Total Assets	11,815,403	13,086,546
Current liabilities:
Accounts payable	598,985	656,304
Accrued expenses	3,411,723	3,260,061
Operating lease liabilities	870,592	865,379
Total current liabilities	4,881,300	4,781,744
Derivative financial instruments—warrants	2,020	4,127
Operating lease liabilities, net of current portion	649,621	860,963
Other liabilities	139,044	128,368
Total Liabilities	5,671,985	5,775,202
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock, $0.001 par value, 20,000,000 shares authorized; 277,100 designated as Series A Convertible Preferred Stock; 60,600 shares outstanding at March 31, 2020 and December 31, 2019 with liquidation preference of $606,000 at March 31, 2020 and December 31, 2019; 200,000 designated as Series C Convertible Preferred Stock; 0 shares outstanding at March 31, 2020 and December 31, 2019	60	60
Common stock, $0.0001 par value, 150,000,000 shares authorized; 11,010,587 and 8,593,633 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	8,554	8,312
Additional paid-in capital	219,805,965	217,172,528
Service receivables	(678,656)	(971,673)
Accumulated deficit	(212,992,505)	(208,897,883)
Total stockholders’ equity	6,143,418	7,311,344
Total liabilities and stockholders’ equity	$ 11,815,403	$ 13,086,546

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in USD per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	11,010,587	8,593,633
Common stock, shares outstanding (in shares)	6,436,505	3,831,880
Series A Convertible Preferred Stock
Preferred stock, shares authorized (in shares)	277,100	277,100
Preferred stock, shares outstanding (in shares)	60,600	60,600
Series A Convertible Preferred Stock, liquidation preference (in dollars)	$ 606,000	$ 606,000
Series C Convertible Preferred Stock
Preferred stock, shares authorized (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues [Abstract]
Royalties	$ 67,704	$ 62,021
Total revenues	67,704	62,021
Costs and expenses:
Research and development	2,705,691	2,648,599
Selling, general and administrative	1,486,019	1,375,185
Total operating expenses	4,191,710	4,023,784
Loss from operations	(4,124,006)	(3,961,763)
Interest income	35,823	64,743
Gain (loss) from change in fair value of derivative financial instruments—warrants	2,107	(9,761)
Other income (expense), net	(2,486)	2,010
Net loss	(4,088,562)	(3,904,771)
Preferred stock dividend payable on Series A Convertible Preferred Stock	(6,060)	(6,060)
Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance	0	(268,269)
Net loss attributable to common stockholders	$ (4,094,622)	$ (4,179,100)
Net loss per common share - basic and diluted (in dollars per share)	$ (0.41)	$ (1.02)
Weighted-average shares outstanding - basic and diluted (in shares)	9,910,306	4,086,561

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Service Receivable	Accumulated Deficit
Balance, beginning (in shares) at Dec. 31, 2018		60,600	3,831,879
Balance, beginning at Dec. 31, 2018	$ 10,084,192	$ 60	$ 7,742	$ 202,267,605	$ 0	$ (192,191,215)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	200,067			200,067
Issuance of common stock upon exercise of warrants (in shares)			497,313
Issuance of common stock upon exercise of warrants	3,282,266		$ 50	3,282,216
Issuance of common stock upon vesting of restricted stock units (in shares)			6,362
Issuance of common stock upon vesting of restricted stock units			$ 4	(4)
Preferred stock dividend payable on Series A Convertible Preferred Stock	(6,060)					(6,060)
Net loss	(3,904,771)					(3,904,771)
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses of $40,000 (in shares)		200,000	183,334
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount of $40,000 and $235,640, respectively	(40,000)	$ 200	$ 110	1,634,690	(1,675,000)
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance				268,269		(268,269)
Issuance of common stock for share rounding as a result of reverse stock split (in shares)			6,466
Release of clinical trial funding commitment	70,487				70,487
Balance, ending (in shares) at Mar. 31, 2019		260,600	4,525,354
Balance, ending at Mar. 31, 2019	9,686,181	$ 260	$ 7,906	207,652,843	(1,604,513)	(196,370,315)
Balance, beginning (in shares) at Dec. 31, 2019		60,600	8,593,633
Balance, beginning at Dec. 31, 2019	7,311,344	$ 60	$ 8,312	217,172,528	(971,673)	(208,897,883)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	177,309			177,309
Sale of common stock and warrants (in shares)			(800,000)
Sale of common stock and warrants	(1,000,001)		$ (80)	(999,921)
Issuance of common stock upon exercise of warrants (in shares)			1,610,144
Issuance of common stock upon exercise of warrants	1,456,369		$ 161	1,456,208
Issuance of common stock upon vesting of restricted stock units (in shares)			6,810
Issuance of common stock upon vesting of restricted stock units			$ 1	(1)
Preferred stock dividend payable on Series A Convertible Preferred Stock	(6,060)					(6,060)
Net loss	(4,088,562)					(4,088,562)
Release of clinical trial funding commitment	293,017				293,017
Balance, ending (in shares) at Mar. 31, 2020		60,600	11,010,587
Balance, ending at Mar. 31, 2020	$ 6,143,418	$ 60	$ 8,554	$ 219,805,965	$ (678,656)	$ (212,992,505)

CONDENSED STATEMENT OF STOCKH_2

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)	3 Months Ended
	Mar. 31, 2019USD ($)
Statement of Stockholders' Equity [Abstract]
Cost of issuance of common stock, preferred stock and warrants	$ 40,000
Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment	$ 235,640

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities
Net loss	$ (4,088,562)	$ (3,904,771)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	119,320	126,781
Stock-based compensation expense	177,309	200,067
Change in fair value of derivative financial instruments—warrants	(2,107)	9,761
Release of clinical trial funding commitment	293,017	70,487
Changes in operating assets and liabilities:
Other assets	1,206	15,725
Accounts receivable and unbilled receivable	97,048	52,079
Prepaid expenses	55,506	179,691
Operating lease right-of-use assets	79,796	73,188
Accounts payable and accrued expenses	88,283	3,635
Operating lease liabilities	(206,129)	(186,689)
Other liabilities	10,676	0
Net cash used in operating activities	(3,374,637)	(3,360,046)
Investing activities:
Capital expenditures	0	(5,274)
Net cash used in investing activities	0	(5,274)
Financing activities:
Proceeds from sales of common stock and warrants	1,000,001	0
Costs related to the clinical trial funding commitment	0	(40,000)
Proceeds from exercise of warrants	1,456,369	3,282,266
Net cash provided by financing activities	2,456,370	3,242,266
Net change in cash and cash equivalents	(918,267)	(123,054)
Cash and cash equivalents—Beginning of period	10,195,292	11,453,133
Cash and cash equivalents—End of period	9,277,025	11,330,079
Supplementary disclosure of cash flow activity:
Cash paid for taxes	800	800
Supplemental disclosure of non-cash investing and financing activities:
Preferred stock dividend payable on Series A Convertible Preferred Stock	6,060	6,060
Deemed dividend recognized for beneficial conversion features of Series C Convertible Preferred Stock issuance	0	268,269
Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment	$ 0	$ 1,675,000

CONDENSED STATEMENTS OF CASH _2

CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)	3 Months Ended
	Mar. 31, 2019USD ($)
Statement of Cash Flows [Abstract]
Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment	$ 235,640

Organization and Basis of Prese

Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Business Organization and Overview Trovagene, Inc. (“Trovagene” or the “Company”) headquartered in San Diego, California, is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, Zytiga®-resistant metastatic castration-resistant prostate cancer and relapsed or refractory acute myeloid leukemia. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Trovagene’s intellectual property and proprietary technology enables the Company to analyze circulating tumor DNA (“ctDNA”) and clinically actionable markers. Unique to the Company’s clinical development plan, is the integration of predictive clinical biomarkers to assess patient response to treatment. Basis of Presentation The accompanying unaudited interim condensed financial statements of Trovagene have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2019 included in the Company’s annual report on Form 10-K filed with the SEC on February 27, 2020 . Liquidity Trovagene’s condensed financial statements as of March 31, 2020 have been prepared under the assumption that Trovagene will continue as a going concern, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern. The Company has incurred net losses since its inception and has negative operating cash flows. Considering the Company’s current cash resources, and service receivable related to the clinical trial funding commitment, management projects the Company’s existing resources will be sufficient to fund the Company’s planned operations into the fourth quarter of 2020 . Based on its current business plan and assumptions, the Company expects to continue to incur significant losses and require significant additional capital to further advance its clinical trial programs and support its other operations. The Company has based its cash sufficiency estimates on its current business plan and its assumptions that may prove to be wrong. The Company could utilize its available capital resources sooner than it currently expects, and it could need additional funding to sustain its operations even sooner than currently anticipated. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements. For the foreseeable future, the Company’s ability to continue its operations is dependent upon its ability to obtain additional capital. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. The economic effects of COVID-19 could also have an adverse effect on the Company's ability to raise additional capital. See Note 10 to the condensed financial statements for further information. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of its product candidates, all of which would have a material adverse impact on the Company’s operations. The Company may also be required to: • Seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and • Relinquish licenses or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize themselves, on unfavorable terms. The Company is evaluating the following options to raise additional capital, increase revenue, as well as reduce costs, in an effort to strengthen its liquidity position: • Raising capital through public and private equity offerings; • Introducing operation and business development initiatives to bring in new revenue streams; • Reducing operating costs by identifying internal synergies; and • Engaging in strategic partnerships. Between April 1, 2020 and April 30, 2020 , the Company has received approximately $1,085,000 from the sale of common stock, pre-funded warrants and warrants. In addition, on April 15, 2020 the Company has received a loan of $305,000 through the United States Small Business Administration Payroll Protection Program (see Note 11 for further details.)

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies During the three months ended March 31, 2020, there have been no changes to the Company’s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2019, except as described below. Net Loss Per Share Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share. Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents: The following table sets forth the computation of basic and diluted earnings per share: Three Months 2020 2019 Numerator: Net loss attributable to common shareholders $ (4,094,622 ) $ (4,179,100 ) Net loss used for basic and diluted loss per share $ (4,094,622 ) $ (4,179,100 ) Denominator: Weighted-average shares used to compute basic and diluted net loss per share 9,910,306 4,086,561 Net loss per share attributable to common stockholders: Basic and diluted $ (0.41 ) $ (1.02 ) The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive: March 31, 2020 2019 Options to purchase Common Stock 975,233 80,345 Warrants to purchase Common Stock 10,516,377 3,302,093 Restricted Stock Units 4,491 18,620 Series A Convertible Preferred Stock 877 877 Series C Convertible Preferred Stock — 333,334 11,496,978 3,735,269 Recently Adopted Accounting Pronouncement In August 2018, the FASB issued ASU No. 2018-13 ("ASU 2018-13"), Changes to the Disclosure Requirements for Fair Value Measurement . This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has prospectively adopted ASU 2018-13 as of January 1, 2020 for periods presented after adoption. The adoption of ASU 2018-13 did not have a material impact on the Company's financial statements.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March 31, 2020 and December 31, 2019 : Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 9,209,577 $ — $ — $ 9,209,577 Total Assets $ 9,209,577 $ — $ — $ 9,209,577 Liabilities: Derivative financial instruments — warrants (2) $ — $ — $ 2,020 $ 2,020 Total Liabilities $ — $ — $ 2,020 $ 2,020 Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 10,131,240 $ — $ — $ 10,131,240 Total Assets $ 10,131,240 $ — $ — $ 10,131,240 Liabilities: Derivative financial instruments — warrants (2) $ — $ — $ 4,127 $ 4,127 Total Liabilities $ — $ — $ 4,127 $ 4,127 (1) Included as a component of cash and cash equivalents on the accompanying condensed balance sheets. (2) A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 6 to the condensed financial statements for further information.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consist of the following: As of March 31, As of December 31, Furniture and office equipment $ 775,030 $ 775,030 Leasehold improvements 1,962,230 1,962,230 Laboratory equipment 744,856 744,856 3,482,116 3,482,116 Less—accumulated depreciation and amortization (2,723,613 ) (2,604,293 ) Property and equipment, net $ 758,503 $ 877,823

Leases

Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases	Leases As a lessee, the Company’s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. The Company (as a sublessor) also subleases portions of its facility to third parties under two separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. Master Facility Lease The Company leases a building in San Diego under an operating lease that expires on December 31, 2021. The lease currently requires fixed monthly rent payments of approximately $78,000 , with 3% annual escalation. The lease also contains one five -year renewal option with minimum monthly rent equal to the then-current fair market value, subject to a 3% annual increase. As the Company is not reasonably certain to exercise this option, it has not been included in the calculation of the lease liability or right-of-use asset related to this lease. Facility Subleases As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under two separate sublease agreements, which both expire December 31, 2021. An additional sublease expired on October 31, 2019 and was not renewed. The Company recorded a cease-use loss liability and expense in 2018 pursuant to ASC 420, Exit or Disposal Cost Obligations , representing the total expected shortfall in sublease income for two of the subleases as compared to its required payments for those spaces under the remainder of the master lease term. This liability was being amortized over the remaining lease term until the adoption of ASC 842, whereupon the remaining cease-use loss liability of approximately $487,000 was eliminated and treated as a reduction to the beginning ROU asset value for the master lease as of January 1, 2019. Income will continue to be recognized on a straight-line basis over the term of the sublease. The components of lease expense were as follows: Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 Operating lease cost $ 106,744 $ 113,592 Operating sublease income (72,793 ) (99,937 ) Net operating lease cost $ 33,951 $ 13,655 Supplemental balance sheet information related to leases was as follows: March 31, 2020 December 31, 2019 Operating lease ROU assets $ 617,622 $ 697,418 Current operating lease liabilities $ 870,592 $ 865,379 Non-current operating lease liabilities 649,621 860,963 Total operating lease liabilities $ 1,520,213 $ 1,726,342 Weighted-average remaining lease term–operating leases 1.8 years 2.0 years Weighted-average discount rate–operating leases 6.5 % 6.5 % Supplemental cash flow and other information related to leases was as follows: Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 233,078 $ 226,364 Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows: Year Ending December 31, Operating Leases Sublease Income Net Operating Leases 2020 (excluding the three months ended March 31, 2020) 632,301 (218,380 ) 413,921 2021 968,165 (291,173 ) 676,992 2022 5,868 — 5,868 2023 3,423 — 3,423 Total future minimum lease payments 1,609,757 $ (509,553 ) $ 1,100,204 Less imputed interest (89,544 ) Total $ 1,520,213
Leases	Leases As a lessee, the Company’s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. The Company (as a sublessor) also subleases portions of its facility to third parties under two separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. Master Facility Lease The Company leases a building in San Diego under an operating lease that expires on December 31, 2021. The lease currently requires fixed monthly rent payments of approximately $78,000 , with 3% annual escalation. The lease also contains one five -year renewal option with minimum monthly rent equal to the then-current fair market value, subject to a 3% annual increase. As the Company is not reasonably certain to exercise this option, it has not been included in the calculation of the lease liability or right-of-use asset related to this lease. Facility Subleases As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under two separate sublease agreements, which both expire December 31, 2021. An additional sublease expired on October 31, 2019 and was not renewed. The Company recorded a cease-use loss liability and expense in 2018 pursuant to ASC 420, Exit or Disposal Cost Obligations , representing the total expected shortfall in sublease income for two of the subleases as compared to its required payments for those spaces under the remainder of the master lease term. This liability was being amortized over the remaining lease term until the adoption of ASC 842, whereupon the remaining cease-use loss liability of approximately $487,000 was eliminated and treated as a reduction to the beginning ROU asset value for the master lease as of January 1, 2019. Income will continue to be recognized on a straight-line basis over the term of the sublease. The components of lease expense were as follows: Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 Operating lease cost $ 106,744 $ 113,592 Operating sublease income (72,793 ) (99,937 ) Net operating lease cost $ 33,951 $ 13,655 Supplemental balance sheet information related to leases was as follows: March 31, 2020 December 31, 2019 Operating lease ROU assets $ 617,622 $ 697,418 Current operating lease liabilities $ 870,592 $ 865,379 Non-current operating lease liabilities 649,621 860,963 Total operating lease liabilities $ 1,520,213 $ 1,726,342 Weighted-average remaining lease term–operating leases 1.8 years 2.0 years Weighted-average discount rate–operating leases 6.5 % 6.5 % Supplemental cash flow and other information related to leases was as follows: Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 233,078 $ 226,364 Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows: Year Ending December 31, Operating Leases Sublease Income Net Operating Leases 2020 (excluding the three months ended March 31, 2020) 632,301 (218,380 ) 413,921 2021 968,165 (291,173 ) 676,992 2022 5,868 — 5,868 2023 3,423 — 3,423 Total future minimum lease payments 1,609,757 $ (509,553 ) $ 1,100,204 Less imputed interest (89,544 ) Total $ 1,520,213

Derivative Financial Instrument

Derivative Financial Instruments - Warrants	3 Months Ended
	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments - Warrants	Derivative Financial Instruments — Warrants Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”) or ASC Topic 480-10, Distinguishing Liabilities from Equity (“ASC 480-10”), Trovagene determined that certain warrants issued in connection with the execution of certain equity financings must be recorded as derivative liabilities. In accordance with ASC 815-40 and ASC 480-10, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company’s condensed statements of operations. The Company estimates the fair value of these warrants using the Black-Scholes option pricing model. The range of assumptions and weighted averages used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated were: Three Months Ended March 31, 2020 2019 Range: Estimated fair value of Trovagene common stock $1.01 - $1.24 $3.15 - $3.75 Expected warrant term 2.8 - 3.1 years 3.8 - 4.1 years Risk-free interest rate 0.28 - 1.61% 2.22 - 2.49% Expected volatility of Trovagene common stock 111 - 112% 102 - 105% Dividend yield 0 % 0 % Weighted Average (1)(2) : Fair value of Trovagene common stock $1.01 Expected warrant term 2.8 years Risk-free interest rate 0.28 % Expected volatility of Trovagene common stock 112 % Dividend yield 0 % (1) Weighted average is only disclosed for periods after January 1, 2020 under the adoption of ASU 2018-13. (2) The weighted average was calculated using the relative fair value method. Expected volatility is based on historical volatility of Trovagene’s common stock. The warrants have a transferability provision and based on guidance provided in Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment (“SAB No. 107”) , for instruments issued with such a provision, Trovagene used the remaining contractual term as the expected term of the warrants. The risk-free rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date. The following table sets forth the components of changes in the Company’s derivative financial instruments — warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. Date Description Number of Warrants Derivative Instrument Liability December 31, 2019 Balance of derivative financial instruments — warrants liability 64,496 $ 4,127 Change in fair value of derivative financial instruments — warrants during the period recognized as a gain in the condensed statements of operations — (2,107 ) March 31, 2020 Balance of derivative financial instruments — warrants liability 64,496 $ 2,020

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Stock Options Stock-based compensation expense related to Trovagene equity awards have been recognized in operating results as follows: Three Months Ended March 31, 2020 2019 Included in research and development expense 76,868 110,081 Included in selling, general and administrative expense 100,441 89,986 Total stock-based compensation expense $ 177,309 $ 200,067 The unrecognized compensation cost related to non-vested stock options outstanding at March 31, 2020 and 2019 , net of estimated forfeitures, was $1,048,776 and $165,954 , respectively, which is expected to be recognized over a weighted-average remaining vesting period of 2.1 and 0.8 years , respectively. The weighted-average remaining contractual term of outstanding options as of March 31, 2020 was approximately 8.8 years . The total fair value of stock options vested during the three months ended March 31, 2020 and 2019 were $34,929 and $188,984 , respectively. The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated: Three Months Ended March 31, 2020 2019 Risk-free interest rate 0.93 % 2.33 % Dividend yield 0 % 0 % Expected volatility of Trovagene common stock 102 % 99 % Expected term 6.0 years 5.1 years A summary of stock option activity and changes in stock options outstanding is presented below: Total Options Weighted-Average Exercise Price Per Share Intrinsic Value Balance outstanding, December 31, 2019 1,015,418 $ 12.77 $ — Granted 5,000 $ 0.74 Canceled / Forfeited (44,910 ) $ 2.67 Expired (275 ) $ 259.20 Balance outstanding, March 31, 2020 975,233 $ 13.10 $ 1,350 Exercisable at March 31, 2020 72,725 $ 144.72 $ — On June 6, 2019, the number of authorized shares in the Trovagene 2014 Equity Incentive Plan (“2014 EIP”) was increased from 243,056 to 1,243,056 . As of March 31, 2020 , there were 207,798 shares available for issuance under the 2014 EIP. Restricted Stock Units A summary of the RSU activity is presented below: Number of Shares Weighted-Average Grant Date Fair Value Per Share Intrinsic Value Non-vested RSUs outstanding, December 31, 2019 11,301 $ 15.38 $ 14,013 Vested (6,810 ) $ 13.98 $ 9,073 Non-vested RSUs outstanding, March 31, 2020 4,491 $ 17.50 $ 4,536 The total fair value of vested RSUs during the three months ended March 31, 2020 and 2019 were $95,170 and $126,983 , respectively. Warrants A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below: Total Warrants (1) Weighted-Average Exercise Price Per Share (1) Weighted-Average Remaining Contractual Term (1) Balance outstanding, December 31, 2019 10,589,482 $ 4.08 3.7 years Granted 931,967 $ 0.95 Exercised (1,005,072 ) $ 1.56 Balance outstanding, March 31, 2020 10,516,377 $ 4.04 3.6 years (1) Balance outstanding as of March 31, 2020 excludes 131,967 pre-funded warrants to purchase shares of common stock at a nominal exercise price of $0.01 per share. These pre-funded warrants were exercised on April 28, 2020, see Note 11 to the condensed financial statements for further information. Series C Convertible Preferred Stock and Service Receivable On January 25, 2019, the Company entered into a Master Services Agreement and a Stock and Warrant Subscription Agreement with PoC Capital, LLC (“PoC”), whereby PoC agreed to finance $1.675 million in clinical studies, including the development costs associated with Phase 1b/2 trial of onvansertib in combination with FOLFIRI and Avastin ® in patients with metastatic Colorectal Cancer (“mCRC”) harboring KRAS mutation in exchange for (i) 183,334 shares of common stock, (ii) warrants to purchase an aggregate of 150,000 shares of common stock, with an exercise price of $3.762 per share, expiring on January 25, 2024, and (iii) 200,000 shares of Series C Convertible Preferred Stock, each share of which was convertible into 1.67 shares of common stock. In April of 2019, all 200,000 shares of Series C Convertible Preferred Stock were converted into 333,333 shares of the Company's common stock. As of March 31, 2020 , there were no shares of Series C Convertible Preferred Stock outstanding. The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and nonforfeitable. Since the equity awards were for clinical trial services yet to be provided, the Company recognized $1.675 million service receivables as contra equity. The Company releases the service receivables as clinical trial services are performed. The conversion feature of the Series C Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series C Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $0.3 million related to the beneficial conversion feature arising from the issuance of Series C Convertible Preferred Stock. This non-cash deemed dividend increased the Company’s net loss attributable to common stockholders and net loss per share.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Executive and Consulting Agreements Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. Research and Development and Clinical Trial Agreements In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Trovagene refers to as onvansertib. Onvansertib is an oral, investigative drug and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company plans to develop onvansertib in patients with leukemias/lymphomas and solid tumor cancers. Upon execution of the agreement, the Company paid $2.0 million in license fees which were expensed to research and development costs. The Company was committed to order $1.0 million of future services provided by Nerviano, such as the cost to manufacture drug product, no later than June 30, 2019, and these services have been purchased. Terms of the agreement also provide for the Company to pay royalties based on certain development and sales milestones. The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of human diagnostics and oncology therapeutics. License fees are generally calculated as a percentage of product revenues, with rates that vary by agreement. For the three months ended March 31, 2020 and 2019 , payments have not been material. Litigation Trovagene does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company’s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company’s business or financial condition.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions In November 2018, the Company entered into a Material Transfer Agreement (“MTA”) with Leucadia Life Sciences (“Leucadia”) pursuant to which Leucadia will develop a PCR-based assay for onvansertib for Acute Myeloid Leukemia (“AML”). The Company’s CEO, Dr. Thomas Adams, is a principal stockholder of Leucadia. In connection with the MTA, the Company entered into a consulting agreement with Tommy Adams, Co-Founder & Chief Operating Officer of Leucadia, who is the son of Dr. Adams. During the three months ended March 31, 2020 and 2019 , the Company incurred and recorded approximately $276,000 and $245,000 respectively, of research and development expenses for services performed by Leucadia and Tommy Adams.

COVID-19 COVID-19

COVID-19 COVID-19	3 Months Ended
	Mar. 31, 2020
Unusual or Infrequent Items, or Both [Abstract]
COVID-19	COVID-19 The COVID-19 outbreak in the United States has caused significant business disruption. The extent of the impact of COVID-19 on the Company's operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, and impact on the Company's clinical trials, employees and vendors, all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company's financial condition or results of operations is uncertain. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of Company to complete certain clinical trials and other efforts required to advance the development of its drugs and raise additional capital. In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES ACT”) was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer’s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The CARES did not have a material impact on our income tax provision for the three months ended March 31, 2020 . We continue to evaluate the impact of the CARES Act on our financial position, results of operations and cash flows. On April 15, 2020, the Company was granted a loan pursuant to the Paycheck Protection Program under Division A, Title I of the CARES Act (see Note 11).

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Event	Subsequent Events Private Placement On April 9, 2020, the Company entered into a securities purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which it sold to LPC, (i) in a registered direct offering, an aggregate of (a) 904,970 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”) and (b) Series K pre-funded warrants (the “Series K Pre-Funded Warrants”) to purchase up to 255,000 shares (the “Series K Warrant Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), which will be exercisable immediately upon issuance for a period of five years after the date of issuance, and (ii) in a concurrent private placement, Series L warrants (the “Series L Warrants”) to purchase up to 1,159,970 shares (the “Series L Warrant Shares”) of Common Stock, for aggregate gross proceeds to the Company of approximately $1.084 million , before deducting estimated offering expenses payable by the Company. On April 28, 2020 LPC exercised 255,000 Series K Pre-Funded Warrants. Small Business Administration Payroll Protection Program Loan On April 15, 2020, the Company was granted a loan (the “Loan”) from JPMorgan Chase Bank, N.A. in the aggregate amount of $305,000 , pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act. The Loan, which was in the form of a Note dated April 15, 2020 issued by the Company, matures on April 15, 2022 and bears interest at a rate of 0.98% per annum, payable monthly commencing on November 15, 2020. The Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, rent, and utilities. The Company intends to use the entire Loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. Amendment to 2014 Equity Incentive Plan On April 16, 2020 the 2014 Equity Incentive Plan was approved by the shareholders and amended to increase the number of shares of common stock reserved for issuance thereunder to 2,243,056 from 1,243,056 . Exercise of Series I Pre-Funded Warrants On April 28, 2020 LPC exercised 131,967 Series I Pre-Funded Warrants.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Net Loss Per Share	Net Loss Per Share Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.
Recently Adopted Accounting Pronouncement	Recently Adopted Accounting Pronouncement In August 2018, the FASB issued ASU No. 2018-13 ("ASU 2018-13"), Changes to the Disclosure Requirements for Fair Value Measurement . This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has prospectively adopted ASU 2018-13 as of January 1, 2020 for periods presented after adoption. The adoption of ASU 2018-13 did not have a material impact on the Company's financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Schedule of Computation of Basic and Diluted Earnings per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months 2020 2019 Numerator: Net loss attributable to common shareholders $ (4,094,622 ) $ (4,179,100 ) Net loss used for basic and diluted loss per share $ (4,094,622 ) $ (4,179,100 ) Denominator: Weighted-average shares used to compute basic and diluted net loss per share 9,910,306 4,086,561 Net loss per share attributable to common stockholders: Basic and diluted $ (0.41 ) $ (1.02 )
Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive: March 31, 2020 2019 Options to purchase Common Stock 975,233 80,345 Warrants to purchase Common Stock 10,516,377 3,302,093 Restricted Stock Units 4,491 18,620 Series A Convertible Preferred Stock 877 877 Series C Convertible Preferred Stock — 333,334 11,496,978 3,735,269

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of the Company’s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy	The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March 31, 2020 and December 31, 2019 : Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 9,209,577 $ — $ — $ 9,209,577 Total Assets $ 9,209,577 $ — $ — $ 9,209,577 Liabilities: Derivative financial instruments — warrants (2) $ — $ — $ 2,020 $ 2,020 Total Liabilities $ — $ — $ 2,020 $ 2,020 Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 10,131,240 $ — $ — $ 10,131,240 Total Assets $ 10,131,240 $ — $ — $ 10,131,240 Liabilities: Derivative financial instruments — warrants (2) $ — $ — $ 4,127 $ 4,127 Total Liabilities $ — $ — $ 4,127 $ 4,127 (1) Included as a component of cash and cash equivalents on the accompanying condensed balance sheets. (2) A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 6 to the condensed financial statements for further information.

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Components of Property and Equipment	Property and equipment consist of the following: As of March 31, As of December 31, Furniture and office equipment $ 775,030 $ 775,030 Leasehold improvements 1,962,230 1,962,230 Laboratory equipment 744,856 744,856 3,482,116 3,482,116 Less—accumulated depreciation and amortization (2,723,613 ) (2,604,293 ) Property and equipment, net $ 758,503 $ 877,823

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Summary of Lease Expense and Supplemental Cash Flow Information	The components of lease expense were as follows: Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 Operating lease cost $ 106,744 $ 113,592 Operating sublease income (72,793 ) (99,937 ) Net operating lease cost $ 33,951 $ 13,655 Supplemental cash flow and other information related to leases was as follows: Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 233,078 $ 226,364
Supplemental Balance Sheet Information	Supplemental balance sheet information related to leases was as follows: March 31, 2020 December 31, 2019 Operating lease ROU assets $ 617,622 $ 697,418 Current operating lease liabilities $ 870,592 $ 865,379 Non-current operating lease liabilities 649,621 860,963 Total operating lease liabilities $ 1,520,213 $ 1,726,342 Weighted-average remaining lease term–operating leases 1.8 years 2.0 years Weighted-average discount rate–operating leases 6.5 % 6.5 %
Summary of Future Minimum Lease Payments	Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows: Year Ending December 31, Operating Leases Sublease Income Net Operating Leases 2020 (excluding the three months ended March 31, 2020) 632,301 (218,380 ) 413,921 2021 968,165 (291,173 ) 676,992 2022 5,868 — 5,868 2023 3,423 — 3,423 Total future minimum lease payments 1,609,757 $ (509,553 ) $ 1,100,204 Less imputed interest (89,544 ) Total $ 1,520,213

Derivative Financial Instrume_2

Derivative Financial Instruments - Warrants (Tables) - Black Scholes Option Pricing Method	3 Months Ended
	Mar. 31, 2020
Derivative financial instruments
Schedule of Assumptions Used to Determine the Fair Value of the Warrants	The range of assumptions and weighted averages used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated were: Three Months Ended March 31, 2020 2019 Range: Estimated fair value of Trovagene common stock $1.01 - $1.24 $3.15 - $3.75 Expected warrant term 2.8 - 3.1 years 3.8 - 4.1 years Risk-free interest rate 0.28 - 1.61% 2.22 - 2.49% Expected volatility of Trovagene common stock 111 - 112% 102 - 105% Dividend yield 0 % 0 % Weighted Average (1)(2) : Fair value of Trovagene common stock $1.01 Expected warrant term 2.8 years Risk-free interest rate 0.28 % Expected volatility of Trovagene common stock 112 % Dividend yield 0 % (1) Weighted average is only disclosed for periods after January 1, 2020 under the adoption of ASU 2018-13. (2) The weighted average was calculated using the relative fair value method.
Schedule of Components of Changes in the Company’s Derivative Financial Instruments Liability Balance	The following table sets forth the components of changes in the Company’s derivative financial instruments — warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. Date Description Number of Warrants Derivative Instrument Liability December 31, 2019 Balance of derivative financial instruments — warrants liability 64,496 $ 4,127 Change in fair value of derivative financial instruments — warrants during the period recognized as a gain in the condensed statements of operations — (2,107 ) March 31, 2020 Balance of derivative financial instruments — warrants liability 64,496 $ 2,020

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
Schedule of Stock-Based Compensation Expense		Stock-based compensation expense related to Trovagene equity awards have been recognized in operating results as follows: Three Months Ended March 31, 2020 2019 Included in research and development expense 76,868 110,081 Included in selling, general and administrative expense 100,441 89,986 Total stock-based compensation expense $ 177,309 $ 200,067
Schedule of Assumptions to Estimate Fair Value of Stock Option Awards	The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated: Three Months Ended March 31, 2020 2019 Risk-free interest rate 0.93 % 2.33 % Dividend yield 0 % 0 % Expected volatility of Trovagene common stock 102 % 99 % Expected term 6.0 years 5.1 years
Summary of Stock Option Activity and of Changes in Stock Options Outstanding	A summary of stock option activity and changes in stock options outstanding is presented below: Total Options Weighted-Average Exercise Price Per Share Intrinsic Value Balance outstanding, December 31, 2019 1,015,418 $ 12.77 $ — Granted 5,000 $ 0.74 Canceled / Forfeited (44,910 ) $ 2.67 Expired (275 ) $ 259.20 Balance outstanding, March 31, 2020 975,233 $ 13.10 $ 1,350 Exercisable at March 31, 2020 72,725 $ 144.72 $ —
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the RSU activity is presented below: Number of Shares Weighted-Average Grant Date Fair Value Per Share Intrinsic Value Non-vested RSUs outstanding, December 31, 2019 11,301 $ 15.38 $ 14,013 Vested (6,810 ) $ 13.98 $ 9,073 Non-vested RSUs outstanding, March 31, 2020 4,491 $ 17.50 $ 4,536
Summary of Warrant Activity and Changes in Warrants Outstanding	A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below: Total Warrants (1) Weighted-Average Exercise Price Per Share (1) Weighted-Average Remaining Contractual Term (1) Balance outstanding, December 31, 2019 10,589,482 $ 4.08 3.7 years Granted 931,967 $ 0.95 Exercised (1,005,072 ) $ 1.56 Balance outstanding, March 31, 2020 10,516,377 $ 4.04 3.6 years (1) Balance outstanding as of March 31, 2020 excludes 131,967 pre-funded warrants to purchase shares of common stock at a nominal exercise price of $0.01 per share. These pre-funded warrants were exercised on April 28, 2020, see Note 11 to the condensed financial statements for further information.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Details) - USD ($)	1 Months Ended	3 Months Ended
	Apr. 30, 2020	Mar. 31, 2020	Mar. 31, 2019	Apr. 15, 2020
Subsequent Event [Line Items]
Proceeds from sale of common stock and warrants, net		$ 1,000,001	$ 0
Subsequent Event
Subsequent Event [Line Items]
Proceeds from sale of common stock and warrants, net	$ 1,085,000
Note payable				$ 305,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Net Loss Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Numerator:
Net loss attributable to common shareholders	$ (4,094,622)	$ (4,179,100)
Net loss used for basic and diluted loss per share	$ (4,094,622)	$ (4,179,100)
Denominator:
Weighted-average shares used to compute basic and diluted net loss per share (in shares)	9,910,306	4,086,561
Net loss per share attributable to common stockholders:
Basic and diluted (in dollars per share)	$ (0.41)	$ (1.02)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	11,496,978	3,735,269
Stock Option
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	975,233	80,345
Warrants
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	10,516,377	3,302,093
Restricted Stock Units (RSUs)
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	4,491	18,620
Series A Preferred Stock
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	877	877
Series C Convertible Preferred Stock
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	0	333,334

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Assets and Liabilities (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Liabilities:
Derivative financial instruments—warrants (2)	$ 2,020	$ 4,127
Estimate of Fair Value Measurement | Recurring basis
Assets:
Money market fund	9,209,577	10,131,240
Total Assets	9,209,577	10,131,240
Liabilities:
Derivative financial instruments—warrants (2)	2,020	4,127
Total Liabilities	2,020	4,127
Estimate of Fair Value Measurement | Recurring basis | Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)
Assets:
Money market fund	9,209,577	10,131,240
Total Assets	9,209,577	10,131,240
Liabilities:
Derivative financial instruments—warrants (2)	0	0
Total Liabilities	0	0
Estimate of Fair Value Measurement | Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Money market fund	0	0
Total Assets	0	0
Liabilities:
Derivative financial instruments—warrants (2)	0	0
Total Liabilities	0	0
Estimate of Fair Value Measurement | Recurring basis | Significant Unobservable Inputs (Level 3)
Assets:
Money market fund	0	0
Total Assets	0	0
Liabilities:
Derivative financial instruments—warrants (2)	2,020	4,127
Total Liabilities	$ 2,020	$ 4,127

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Property, equipment and depreciation and amortization
Property and equipment, gross	$ 3,482,116	$ 3,482,116
Less—accumulated depreciation and amortization	(2,723,613)	(2,604,293)
Property and equipment, net	758,503	877,823
Furniture and office equipment
Property, equipment and depreciation and amortization
Property and equipment, gross	775,030	775,030
Leasehold improvements
Property, equipment and depreciation and amortization
Property and equipment, gross	1,962,230	1,962,230
Laboratory equipment
Property, equipment and depreciation and amortization
Property and equipment, gross	$ 744,856	$ 744,856

Leases - Narrative (Details)

Leases - Narrative (Details)	3 Months Ended
	Mar. 31, 2020USD ($)renewal_optionlease	Dec. 31, 2019USD ($)	Jan. 01, 2019USD ($)
Lessee, Lease, Description [Line Items]
Monthly rent payments	$ 78,000
Annual rent increase, percentage	3.00%
Number of lease renewals | renewal_option	1
Renewal term	5 years
Number of subleases | lease	2
Decrease in operating lease right-of-use assets	$ (617,622)	$ (697,418)
Accounting Standards Update 2016-02
Lessee, Lease, Description [Line Items]
Decrease in operating lease right-of-use assets			$ (487,000)

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating lease cost	$ 106,744	$ 113,592
Operating sublease income	(72,793)	(99,937)
Net operating lease cost	$ 33,951	$ 13,655

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease ROU assets	$ 617,622	$ 697,418
Current operating lease liabilities	870,592	865,379
Non-current operating lease liabilities	649,621	860,963
Total operating lease liabilities	$ 1,520,213	$ 1,726,342
Weighted-average remaining lease term–operating leases	1 year 9 months 4 days	2 years
Weighted-average discount rate–operating leases	6.50%	6.50%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating cash flows from operating leases	$ 233,078	$ 226,364

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Operating Leases
2019 (excluding the nine months ended September 30, 2019)	$ 632,301
2021	968,165
2022	5,868
2023	3,423
Total future minimum lease payments	1,609,757
Less imputed interest	(89,544)
Total	1,520,213	$ 1,726,342
Sublease Income
2019 (excluding the nine months ended September 30, 2019)	(218,380)
2021	(291,173)
2022	0
2023	0
Total future minimum lease payments	(509,553)
Net Operating Leases
2019 (excluding the nine months ended September 30, 2019)	413,921
2021	676,992
2022	5,868
2023	3,423
Total future minimum lease payments	$ 1,100,204

Derivative Financial Instrume_3

Derivative Financial Instruments - Warrants (Details)	3 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2019USD ($)$ / shares	Sep. 30, 2018
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares) | shares	10,589,482
Balance of warrants outstanding at the end of the period (in shares) | shares	10,516,377
Balance of derivative financial instruments liability at the beginning of the period	$ 4,127
Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations	(2,107)	$ 9,761
Balance of derivative financial instruments liability at the end of the period	$ 2,020
Warrants | Weighted Average
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share) | $ / shares	$ 1.01
Warrants | Black Scholes Option Pricing Method
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares) | shares	64,496
Balance of warrants outstanding at the end of the period (in shares) | shares	64,496
Balance of derivative financial instruments liability at the beginning of the period	$ 4,127
Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations	(2,107)
Balance of derivative financial instruments liability at the end of the period	$ 2,020
Warrants | Black Scholes Option Pricing Method | Minimum
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share) | $ / shares	$ 1.01	$ 3.15
Warrants | Black Scholes Option Pricing Method | Maximum
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share) | $ / shares	$ 1.24	$ 3.75
Expected warrant term | Warrants | Weighted Average
Range of assumptions used to determine the fair value of warrants
Expected warrant term	2 years 9 months 8 days
Expected warrant term | Warrants | Black Scholes Option Pricing Method | Minimum
Range of assumptions used to determine the fair value of warrants
Expected warrant term	2 years 9 months 19 days	3 years 9 months 19 days
Expected warrant term | Warrants | Black Scholes Option Pricing Method | Maximum
Range of assumptions used to determine the fair value of warrants
Expected warrant term	3 years 1 month	4 years 1 month
Risk-free interest rate | Warrants | Weighted Average
Range of assumptions used to determine the fair value of warrants
Measurement input	0.0028
Risk-free interest rate | Warrants | Black Scholes Option Pricing Method | Minimum
Range of assumptions used to determine the fair value of warrants
Measurement input	0.0028	0.0222
Risk-free interest rate | Warrants | Black Scholes Option Pricing Method | Maximum
Range of assumptions used to determine the fair value of warrants
Measurement input	0.0161	0.0249
Expected volatility of Trovagene common stock | Warrants | Weighted Average
Range of assumptions used to determine the fair value of warrants
Measurement input	1.12
Expected volatility of Trovagene common stock | Warrants | Black Scholes Option Pricing Method | Minimum
Range of assumptions used to determine the fair value of warrants
Measurement input	1.11	1.02
Expected volatility of Trovagene common stock | Warrants | Black Scholes Option Pricing Method | Maximum
Range of assumptions used to determine the fair value of warrants
Measurement input	1.12	1.05
Dividend yield | Warrants | Weighted Average
Range of assumptions used to determine the fair value of warrants
Measurement input	0
Dividend yield | Warrants | Black Scholes Option Pricing Method
Range of assumptions used to determine the fair value of warrants
Measurement input	0		0

Stockholders' Equity - Stock-ba

Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation expense
Total stock based compensation expense	$ 177,309	$ 200,067
Options vested, fair value	34,929	188,984
Research and Development Expense
Stock-based compensation expense
Total stock based compensation expense	76,868	110,081
Selling, general and administrative expense
Stock-based compensation expense
Total stock based compensation expense	100,441	89,986
Stock Option
Stock-based compensation expense
Unrecognized compensation cost	$ 1,048,776	$ 165,954
Weighted-average remaining vesting period for recognition	2 years 1 month	9 months 19 days
Options outstanding, weighted average contractual life	8 years 9 months

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Jun. 06, 2019	Jun. 05, 2019
Stock Option
Weighted-average assumptions
Risk-free interest rate	0.93%	2.33%
Dividend yield (as a percent)	0.00%	0.00%
Expected volatility (as a percent)	102.00%	99.00%
Expected term	6 years	5 years 1 month 23 days
Number of Options
Balance outstanding at the beginning of the period (in shares)	1,015,418
Granted (in shares)	5,000
Cancelled / Forfeited (in shares)	(44,910)
Expired (in shares)	(275)
Balance outstanding at the end of the period (in shares)	975,233
Exercisable at the end of the period (in shares)	72,725
Weighted Average Exercise Price Per Share
Balance outstanding at the beginning of the period (in USD per share)	$ 12.77
Granted (in USD per share)	0.74
Canceled / Forfeited (in USD per share)	2.67
Expired (in USD per share)	259.20
Balance outstanding at the end of the period (in USD per share)	13.10
Exercisable at the end of the period (in USD per share)	$ 144.72
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Options outstanding, intrinsic value	$ 1,350		$ 0
Vested and exercisable at the end of the period, intrinsic value	$ 0
2014 EIP
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Authorized shares under the plan (in shares)				1,243,056	243,056
Number of remaining shares available for issuance (in shares)	207,798

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Units (Details) - Restricted Stock Units (RSUs) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Number of Shares
Non-vested at beginning of period (in shares)	11,301
Vested (in shares)	(6,810)
Non-vested at end of period (in shares)	4,491
Weighted-Average Grant Date Fair Value Per Share
Nonvested, weighted average grant date fair value at end of period (in USD per share)	$ 15.38
Vested, weighted average grant date fair value (in USD per share)	13.98
Nonvested, weighted average grant date fair value at end of period (in USD per share)	$ 17.50
Equity instruments other than options, aggregate intrinsic value, nonvested	$ 4,536		$ 14,013
Equity instruments other than options, aggregate intrinsic value, vested	9,073
Equity instruments other than options, vested in period, fair value	$ 95,170	$ 126,983

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants (Details) - $ / shares	Apr. 28, 2020	Mar. 31, 2020	Dec. 31, 2019
Number of Warrants
Balance of warrants outstanding at the end of the period (in shares)		10,516,377	10,589,482
Granted (in shares)		931,967
Exercised (in shares)		(1,005,072)
Balance of warrants outstanding at the beginning of the period (in shares)		10,589,482
Weighted Average Exercise Price Per Share
Weighted average exercise price of warrants at the beginning of the period (in USD per share)		$ 4.08
Granted (in USD per share)		0.95
Exercised (in USD per share)		1.56
Weighted average exercise price of warrants at the end of the period (in USD per share)		$ 4.04	$ 4.08
Term
Weighted-Average Remaining Contractual Term		3 years 7 months	3 years 8 months 21 days
Pre-Funded Warrants
Number of Warrants
Exercised (in shares)		(131,967)
Subsequent Event | Pre-Funded Warrants
Number of Warrants
Exercised (in shares)	(131,967)

Stockholders' Equity - Series C

Stockholders' Equity - Series C Convertible Preferred Stock (Details) - USD ($)	Jan. 25, 2019	Apr. 30, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Class of Stock [Line Items]
Warrants granted (in shares)			931,967
Shares issued upon conversion (in shares)		333,333
Service receivable	$ 1,675,000		$ 678,656		$ 971,673
Deemed dividend recognized for beneficial conversion features of Series C Convertible Preferred Stock issuance			$ 0	$ 268,269
Series C Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding (in shares)			0		0
Deemed dividend recognized for beneficial conversion features of Series C Convertible Preferred Stock issuance			$ 300,000
Private Placement
Class of Stock [Line Items]
Proceeds from sales of common stock and warrants, net of expenses of $1,336,123 and $575,516, respectively	$ 1,675,000
Warrants granted (in shares)	150,000
Exercise price of warrants (in USD per share)	$ 3.762
Common Stock | Private Placement
Class of Stock [Line Items]
Shares of common stock issued (in shares)	183,334
Shares issued upon conversion (in shares)	1.67
Series C Convertible Preferred Stock
Class of Stock [Line Items]
Shares converted (in shares)		200,000
Series C Convertible Preferred Stock | Private Placement
Class of Stock [Line Items]
Shares of common stock issued (in shares)	200,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - Nerviano - USD ($) $ in Millions	1 Months Ended
	Mar. 31, 2017	Mar. 13, 2017
Other Commitments [Line Items]
Other commitment		$ 1
Licensing Agreements
Other Commitments [Line Items]
Research and development expense	$ 2

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Affiliated Entity
Related Party Transaction [Line Items]
Research and development expense	$ 276	$ 245

Subsequent Event (Details)

Subsequent Event (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 28, 2020	Apr. 10, 2020	Mar. 31, 2020	Apr. 16, 2020	Apr. 15, 2020	Dec. 31, 2019	Jun. 06, 2019	Jun. 05, 2019
Subsequent Event [Line Items]
Common stock, par value (in USD per share)			$ 0.0001			$ 0.0001
Warrants granted (in shares)			931,967
Exercised (in shares)			1,005,072
Subsequent Event
Subsequent Event [Line Items]
Note payable					$ 305
Interest rate					0.98%
Registered Direct Offering | Subsequent Event
Subsequent Event [Line Items]
Sale of stock, number of shares issued (in shares)		904,970
Proceeds from sale of stock and stock equivalents		$ 1,100
2014 EIP
Subsequent Event [Line Items]
Authorized shares under the plan (in shares)							1,243,056	243,056
2014 EIP | Subsequent Event
Subsequent Event [Line Items]
Authorized shares under the plan (in shares)				2,243,056	1,243,056
Series K Pre-Funded Warrants | Registered Direct Offering | Subsequent Event
Subsequent Event [Line Items]
Exercised (in shares)	255,000
Series L Warrants | Registered Direct Offering | Subsequent Event
Subsequent Event [Line Items]
Warrants granted (in shares)		1,159,970
Pre-Funded Warrants
Subsequent Event [Line Items]
Exercised (in shares)			131,967
Pre-Funded Warrants | Subsequent Event
Subsequent Event [Line Items]
Exercised (in shares)	131,967